Volume 6.08 | Mar 6

Cord Blood News 6.08 March 6, 2014
Cord Blood News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Circulating Hematopoietic Stem and Progenitor Cells Are Myeloid-Biased in Cancer Patients
By using cord blood-derived CD34+ cells, researchers developed an in vitro short-term culture model to effectively induce the rapid generation of myeloid-derived suppressor cells (MDSCs). They found that, among the factors produced by various tumors, GM-CSF, granulocyte colony-stimulating factor, and IL-6 could not only promote the myeloid-biased differentiation, but also induce the differentiation of myeloid precursors into functional MDSCs. [Proc Natl Acad Sci USA] Abstract
Take the "if" out of "diff": Reduce variability when differentiating to hematopoietic cells
PUBLICATIONS (Ranked by impact factor of the journal)
Human Amniotic Fluid Stem Cells Possess the Potential to Differentiate into Primordial Follicle Oocytes In Vitro
To investigate the pluripotency of human amniotic fluid stem cells (hAFSCs) and their ability to differentiate into germ cells, scientists isolated a CD117+/CD44+ hAFSC line that showed fibroblastoid morphology and intrinsically expressed both stem cell markers (OCT4, NANOG, SOX2) and germ cell markers (DAZL, STELLA). [Biol Reprod] Abstract | Full Article

Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A CIBMTR-Eurocord Analysis
Researchers studied acute myeloid leukemia patients over age 50 in CR1 after adult unrelated donor or umbilical cord blood transplantations. [Biol Blood Marrow Transplant] Abstract

Antibody against Immunoglobulin E Contained in Blood Components as Causative Factor for Anaphylactic Transfusion Reactions
Two bags of fresh-frozen plasma obtained from a donor (index donor) were implicated in two cases of anaphylactic transfusion reactions. The serum prepared from the index donor plasma transfused into the second patient (Patient 2) was evaluated using cord blood-derived mast cells incubated with Patient 2 plasma. [Transfusion] Abstract

Low Rate of Infusional Toxicity after Expanded Cord Blood Transplantation
Investigators concluded that the infusion of unmanipulated followed by expanded cord blood products is a safe procedure associated with a low probability of inducing severe reactions. [Cytotherapy] Abstract

A Comparison of Intravenous and Intradiscal Delivery of Multipotential Stem Cells on the Healing of Injured Intervertebral Disk
Recent studies indicated that multipotential stem cells from human umbilical cord blood home to injured sites and induce local therapeutic changes, thereby potentially addressing the drawbacks of direct delivery. Researchers tested the effects of these cells on injured intervertebral disk using a mouse model of puncture-induced degeneration via two delivery methods. [J Orthop Res] Abstract

Multilineage Potential Research of Bovine Amniotic Fluid Mesenchymal Stem Cells
Researchers aimed to obtain and characterize bovine amniotic fluid mesenchymal stem cells. [Int J Mol Sci] Abstract | Download Full Article

Effect and Mechanisms of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells on Type 1 Diabetes in NOD Model
Mesenchymal stem cells derived from Wharton’s jelly (WJ-MSCs) own a peculiar immunomodulatory feature and might reverse the inflammatory destruction and repair the function of β-cells. Sixty NOD mice were divided into four groups, including normal control group, WJ-MSCs prevention group (before onset), WJ-MSCs treatment group (after onset), and diabetic control group. [Endocrine] Abstract

The Role of Albumin and PPAR-α in Differentiation-Dependent Change of Fatty Acid Profile during Differentiation of Mesenchymal Stem Cells to Hepatocyte-Like Cells
The effect of hepatogenic differentiation on fatty acid profile and the expression of proliferator-activated receptors-α (PPAR-α) have been studied. For this purpose, mesenchymal stem cells isolated from human umbilical cord were differentiated into hepatocyte-like cells on selective culture media. [Cell Biochem Funct] Abstract

Hematopoietic Course for Cord Blood - Learn More and Register
Developing Cellular Therapies for Retinal Degenerative Diseases
Two phase I clinical trials using embryonic stem cell-derived RPE are already underway and several others using both pluripotent and multipotent adult stem cells are in earlier stages of development. These clinical trials will use a variety of cell types, including embryonic or induced pluripotent stem cell-derived RPE, bone marrow- or umbilical cord-derived mesenchymal stem cells, fetal neural or retinal progenitor cells, and adult RPE stem cells-derived RPE. [Invest Ophthalmol Vis Sci] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Attend the 9th Annual World Stem Cells & Regenerative Medicine Congress in London!
CBR Announces Poster Presentation
The poster presents key findings from a recent survey of families with at least one child who has newborn stem cells stored with Cord Blood Registry® (CBR®). Of the families completing the questionnaire, 1.87% reported an immediate family history of at least one transplant indication and 17.04% reported at least one regenerative indication. [Press release from PR Newswire Association LLC discussing research presented at the 2014 BMT Tandem Meetings, Grapevine] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
US FDA Approves Pluristem’s Commercial Scale Cell Manufacturing Process
Pluristem Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has reviewed Pluristem’s comparability studies of its placental expanded cell products and granted approval for the Company to manufacture these products in its new commercial-scale cell manufacturing facility. [Pluristem Therapeutics, Inc.] Press Release

Mediware Launches Transtem™ Patient 2014 Software for BMT
Mediware Information Systems, Inc. announced the launch of the new Transtem Patient 2014 software for Blood and Marrow Transplant (BMT) programs. This single, specialized software solution allows transplant staff to efficiently manage patient, donor and product information all in one place, with the highest level of safety and security. [Mediware Information Systems, Inc.] Press Release
Guidance for Industry: BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System [US Food and Drug Administration, Center for Biologics Evaluation and Research]

Guidance for Industry and FDA Staff: IND Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System [US Food and Drug Administration, Center for Biologics Evaluation and Research]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Stem Cells and BioProcessing
June 3, 2014
London, United Kingdom

NEW Society for Hematology and Stem Cells (ISEH) 43rd Annual Scientific Meeting
August 21-24, 2014
Montreal, Canada

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Position – Human Stem Cell Biology and Hematopoiesis (Johns Hopkins University School of Medicine)

NEW Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

NEW Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

PhD Studentship – Stem Cell Research (University Medical Center Ulm)

Postdoctoral Position – Hematopoietic Stem Cell Self-Renewal (University of Iowa)

Director – Clinical Immunogenetics Laboratory (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Hematopoietic Stem Cell Biology (St. Jude Children’s Research Hospital)

Postdoctoral Positions – Hematopoietic Stem Cell Physiology and Bone Marrow Failure (University of Michigan)

Assistant Professorship – Hematopoietic Stem Cells and Microenvironment (University of Zurich)

Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us